Immutep Ltd. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, with operations in Europe and the United States, the company specializes in therapeutics based on the Lymphocyte Activation Gene-3 (LAG-3) immune control mechanism. Its lead product candidate, eftilagimod alpha (efti), is a first-in-class soluble LAG-3 fusion protein and antigen-presenting cell agonist currently advancing through clinical trials for various oncology indications, including metastatic breast cancer and head and neck squamous cell carcinoma. The company's pipeline also includes IMP761, an agonist antibody targeting LAG-3 for autoimmune diseases. Immutep advances its clinical programs both independently and through strategic partnerships with major pharmaceutical companies such as GlaxoSmithKline and Novartis. The company generates revenue primarily through partnership milestone payments, research collaboration funding, and licensing agreements.
